SlideShare a Scribd company logo
Guidelines on ADR reporting
Presented by;
K. Sai Lakshmi
B-Pharmacy, final year,
(2016-2020)
Balaji College of Pharmacy.
A.PATIENT INFORMATION
B.SUSPECTED DRUGS
C.SUSPECTED ADVERSE DRUG
REACTION
D.OTHER MEDICATIONS
E.REPORTER
A. PATIENT INFORMATION;
1.Patient Details
 Patient name or initials: A reporter should mention the name of
the patient or initials of a patient.
For e.g.: Ngawang Dema or ND (whichever is convenient).
 Age at time of event or date of birth: A reporter must report either
the date of birth or age of the patient at the time the event or
reaction occurred.
 Sex: A reporter must mention the gender of the patient.
 Weight: If known, the weight of the patient should be in
kilograms(kg).
2. Relevant tests/Laboratory data
 A reporter must mention any laboratory data (if available).
3. Other Relevant history
 A reporter must mention any relevant history pertaining to the
patient including pre-existing medical conditions
e.g.: Allergies, pregnancy, alcohol use, hepatic or renal dysfunction.
B. SUSPECTED DRUGS;
 It may be one drug or more than one drug.
 The details of suspected medications such as the drug name
(brand or generic name), manufacturer, batch no / lot no, expiry
date, dose used, route used, dates of therapy started and stopped,
and indication of use must be provided by the reporter.
C. SUSPECTED ADVERSE DRUG REACTION;
1. Describe reaction and any treatment given:
 A reporter must briefly describe the event in terms of nature, localization
etc.
For eg; patient developed rash over upper and lower limbs.
 The reporter must be also indicate if any treatment is given againist the
Suspected Adverse Drug Reaction.
 Reporter must also mention if the suspected drugs was withdrawn or
continued.
 Date of reaction started; A reporter must the date on which the reaction
was first occurred.
 Date of reaction stopped; If the reaction recovered, the date on which the
reaction recovered should be reported.
 Outcomes: The reporter must tick the outcomes of the event as;
Recovered- if the patient has recovered from the event
Recovering- if the patient is recovering from the existing adverse event
Continuing-if the patient is continuing to have the symptoms of the adverse
event which occurred.
2. Seriousness of the reaction:
 If any event is serious in nature, a reporter must selected the
appropriate reason for seriousness e.g.:
 Death-if the patient died due to the adverse event
 Hospitalization/prolonged-if the adverse event led to
hospitalization or increased the hospital stay of the patient.
 Life-threatening-if patient was at substantial risk of drying
because of the adverse event.
 Significant Disability-if the adverse event resulted in a
substantial disruption of a person`s ability to conduct normal life
functions.
 Congenital anomaly-if exposure of drug prior to conception or
during pregnancy may have resulted in an adverse outcome in the
child.
 Other medically significant- when the event does not fit the
other outcomes, but the event may put the patient at risk and may
require medical or surgical intervention to prevent one of the other
outcomes.
D. OTHER MEDICATIONS;
 A Reporter should include all the details of concomitant drugs
including self medication, Over the Counter medication, herbal
remedies with therapy dates(start and stop date).
E. REPORTER;
 Name and Professional address: A reporter must mention
his/her name and professional address on the form. The
identity of the reporter will be maintained confidential if
necessary.
 Date of report: Mention the date on which he/she reported the
adverse event.
NOTE: For quality reporting, all the above mentioned fields are
essential. In case of incomplete information, the reporter must
take care that at least mandatory fields are present. Following
are the mandatory fields for a valid case report and are marked
with asterisk on the form:
 Patient information: initials, age at onset of reaction,
gender.
 Suspected adverse reaction: A reaction terms, date of
onset of reaction.
 Suspected medication: Drug(s) name, dose and date of
therapy started, indication of use, seriousness and outcome.
 Reporter: Name and address, date of report.
Guidelines on adr reporting

More Related Content

What's hot

Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...
AbhishekJoshi312
 
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
E Poovarasan
 
STATISTICAL METHODS FOR PHARMACOVIGILANCE
STATISTICAL METHODS FOR PHARMACOVIGILANCESTATISTICAL METHODS FOR PHARMACOVIGILANCE
STATISTICAL METHODS FOR PHARMACOVIGILANCE
Sanju Kaladharan
 
Ind enabling studies.
Ind enabling studies.Ind enabling studies.
Ind enabling studies.
Shikha Choudhary
 
Methods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxMethods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptx
PankajKadyan5
 
Clinical Trial Doc.pptx
Clinical Trial Doc.pptxClinical Trial Doc.pptx
Clinical Trial Doc.pptx
AKASHJAIN152187
 
Invivo Carcinogenecity Studies
Invivo Carcinogenecity StudiesInvivo Carcinogenecity Studies
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
SIRAJUDDIN MOLLA
 
Guidelines For ADR Reporting.pptx
Guidelines For ADR Reporting.pptxGuidelines For ADR Reporting.pptx
Guidelines For ADR Reporting.pptx
SohamChakrabarti6
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant Yadav
Kashikant Yadav
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
SnehaKhandale1
 
Schedule y
Schedule  ySchedule  y
Schedule y
kumargourav40
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
AYESHA NAZEER
 
Toxicokinetic evaluation in preclinical studies by Shivam Diwaker
Toxicokinetic evaluation in preclinical studies by Shivam Diwaker Toxicokinetic evaluation in preclinical studies by Shivam Diwaker
Toxicokinetic evaluation in preclinical studies by Shivam Diwaker
Shivam Diwaker
 
Male and female reproductive toxicology
Male and female reproductive toxicologyMale and female reproductive toxicology
Male and female reproductive toxicology
Khadga Raj
 
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptxINTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
E Poovarasan
 
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
helasri gummadi
 
regulatory perspectives of clinical trails
regulatory perspectives of clinical trails regulatory perspectives of clinical trails
regulatory perspectives of clinical trails
Pankaj Maurya
 
Safety pharmacology tier 2
Safety pharmacology  tier 2Safety pharmacology  tier 2
Safety pharmacology tier 2
ragini Dani
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trials
DRx Tejas Kanhed
 

What's hot (20)

Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...
 
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
 
STATISTICAL METHODS FOR PHARMACOVIGILANCE
STATISTICAL METHODS FOR PHARMACOVIGILANCESTATISTICAL METHODS FOR PHARMACOVIGILANCE
STATISTICAL METHODS FOR PHARMACOVIGILANCE
 
Ind enabling studies.
Ind enabling studies.Ind enabling studies.
Ind enabling studies.
 
Methods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxMethods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptx
 
Clinical Trial Doc.pptx
Clinical Trial Doc.pptxClinical Trial Doc.pptx
Clinical Trial Doc.pptx
 
Invivo Carcinogenecity Studies
Invivo Carcinogenecity StudiesInvivo Carcinogenecity Studies
Invivo Carcinogenecity Studies
 
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
 
Guidelines For ADR Reporting.pptx
Guidelines For ADR Reporting.pptxGuidelines For ADR Reporting.pptx
Guidelines For ADR Reporting.pptx
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant Yadav
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
 
Schedule y
Schedule  ySchedule  y
Schedule y
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
Toxicokinetic evaluation in preclinical studies by Shivam Diwaker
Toxicokinetic evaluation in preclinical studies by Shivam Diwaker Toxicokinetic evaluation in preclinical studies by Shivam Diwaker
Toxicokinetic evaluation in preclinical studies by Shivam Diwaker
 
Male and female reproductive toxicology
Male and female reproductive toxicologyMale and female reproductive toxicology
Male and female reproductive toxicology
 
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptxINTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
 
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
 
regulatory perspectives of clinical trails
regulatory perspectives of clinical trails regulatory perspectives of clinical trails
regulatory perspectives of clinical trails
 
Safety pharmacology tier 2
Safety pharmacology  tier 2Safety pharmacology  tier 2
Safety pharmacology tier 2
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trials
 

Similar to Guidelines on adr reporting

Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Dr Sukanta sen
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical Pharmacy
Drpradeepthi
 
triage ppt.pptx
triage ppt.pptxtriage ppt.pptx
triage ppt.pptx
VermaG3
 
Detecting Reporting ADR.pptx
Detecting  Reporting ADR.pptxDetecting  Reporting ADR.pptx
Detecting Reporting ADR.pptx
AjithJs2
 
PvPI ADR reporting communication under pvpi
PvPI ADR reporting  communication under pvpiPvPI ADR reporting  communication under pvpi
PvPI ADR reporting communication under pvpi
chshubham03
 
Detection, reporting and management of adverse events
Detection, reporting and management of adverse eventsDetection, reporting and management of adverse events
Detection, reporting and management of adverse events
Katla Swapna
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
Satya Prakash Dixit
 
Quality Reporting of ADR
Quality Reporting of ADRQuality Reporting of ADR
Quality Reporting of ADR
NazmiLianaAzmi
 
ADR reporting (Clinical Research & Pharmacovigilance).pptx
ADR reporting (Clinical Research & Pharmacovigilance).pptxADR reporting (Clinical Research & Pharmacovigilance).pptx
ADR reporting (Clinical Research & Pharmacovigilance).pptx
Dureshahwar khan
 
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and ChallengesAdverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
ClinosolIndia
 
ICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLSICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLS
Katalyst HLS
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
dabloosaha
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
santoshi sahu
 
Revision of adverse drug reactions.pptx
Revision of adverse drug reactions.pptxRevision of adverse drug reactions.pptx
Revision of adverse drug reactions.pptx
RanitBag1
 
Pharmacovigilance by khaga
Pharmacovigilance by khagaPharmacovigilance by khaga
Pharmacovigilance by khaga
Khadga Raj
 
Adverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & ReportingAdverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & Reporting
Ruella D'Costa Fernandes
 
Pharmacovigilance overview shraddha
Pharmacovigilance  overview shraddhaPharmacovigilance  overview shraddha
Pharmacovigilance overview shraddha
Dr. Shraddha Bhange
 
Patient profile (Taking & Components)
Patient profile (Taking & Components)Patient profile (Taking & Components)
Patient profile (Taking & Components)
Muhammad Arsal
 

Similar to Guidelines on adr reporting (20)

Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical Pharmacy
 
triage ppt.pptx
triage ppt.pptxtriage ppt.pptx
triage ppt.pptx
 
Detecting Reporting ADR.pptx
Detecting  Reporting ADR.pptxDetecting  Reporting ADR.pptx
Detecting Reporting ADR.pptx
 
PvPI ADR reporting communication under pvpi
PvPI ADR reporting  communication under pvpiPvPI ADR reporting  communication under pvpi
PvPI ADR reporting communication under pvpi
 
Detection, reporting and management of adverse events
Detection, reporting and management of adverse eventsDetection, reporting and management of adverse events
Detection, reporting and management of adverse events
 
adverse drug reactions management
adverse drug reactions  managementadverse drug reactions  management
adverse drug reactions management
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Quality Reporting of ADR
Quality Reporting of ADRQuality Reporting of ADR
Quality Reporting of ADR
 
Pharmacovigilance suresh
Pharmacovigilance  sureshPharmacovigilance  suresh
Pharmacovigilance suresh
 
ADR reporting (Clinical Research & Pharmacovigilance).pptx
ADR reporting (Clinical Research & Pharmacovigilance).pptxADR reporting (Clinical Research & Pharmacovigilance).pptx
ADR reporting (Clinical Research & Pharmacovigilance).pptx
 
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and ChallengesAdverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
 
ICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLSICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLS
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Revision of adverse drug reactions.pptx
Revision of adverse drug reactions.pptxRevision of adverse drug reactions.pptx
Revision of adverse drug reactions.pptx
 
Pharmacovigilance by khaga
Pharmacovigilance by khagaPharmacovigilance by khaga
Pharmacovigilance by khaga
 
Adverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & ReportingAdverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & Reporting
 
Pharmacovigilance overview shraddha
Pharmacovigilance  overview shraddhaPharmacovigilance  overview shraddha
Pharmacovigilance overview shraddha
 
Patient profile (Taking & Components)
Patient profile (Taking & Components)Patient profile (Taking & Components)
Patient profile (Taking & Components)
 

More from SaiLakshmi110

Evaluation of cosmetic products
Evaluation of cosmetic productsEvaluation of cosmetic products
Evaluation of cosmetic products
SaiLakshmi110
 
In-vivo; Permeability methods
In-vivo; Permeability methodsIn-vivo; Permeability methods
In-vivo; Permeability methods
SaiLakshmi110
 
Pesticide cycle
Pesticide cyclePesticide cycle
Pesticide cycle
SaiLakshmi110
 
Affinity chromatography
Affinity chromatographyAffinity chromatography
Affinity chromatography
SaiLakshmi110
 
Biological test and assay of Antivenom
Biological test and assay of AntivenomBiological test and assay of Antivenom
Biological test and assay of Antivenom
SaiLakshmi110
 
Systems of human body
Systems of human bodySystems of human body
Systems of human body
SaiLakshmi110
 
New plant varieties
New plant varietiesNew plant varieties
New plant varieties
SaiLakshmi110
 
Industrial designs in IPR
Industrial designs in IPRIndustrial designs in IPR
Industrial designs in IPR
SaiLakshmi110
 
Geographical indications
Geographical indicationsGeographical indications
Geographical indications
SaiLakshmi110
 
Utility models
Utility modelsUtility models
Utility models
SaiLakshmi110
 
Types of oral controll drug delivery system
Types of oral controll drug delivery system Types of oral controll drug delivery system
Types of oral controll drug delivery system
SaiLakshmi110
 
Novel drug delivery system
Novel drug delivery systemNovel drug delivery system
Novel drug delivery system
SaiLakshmi110
 
Targeted drug delivery system
Targeted drug delivery systemTargeted drug delivery system
Targeted drug delivery system
SaiLakshmi110
 

More from SaiLakshmi110 (13)

Evaluation of cosmetic products
Evaluation of cosmetic productsEvaluation of cosmetic products
Evaluation of cosmetic products
 
In-vivo; Permeability methods
In-vivo; Permeability methodsIn-vivo; Permeability methods
In-vivo; Permeability methods
 
Pesticide cycle
Pesticide cyclePesticide cycle
Pesticide cycle
 
Affinity chromatography
Affinity chromatographyAffinity chromatography
Affinity chromatography
 
Biological test and assay of Antivenom
Biological test and assay of AntivenomBiological test and assay of Antivenom
Biological test and assay of Antivenom
 
Systems of human body
Systems of human bodySystems of human body
Systems of human body
 
New plant varieties
New plant varietiesNew plant varieties
New plant varieties
 
Industrial designs in IPR
Industrial designs in IPRIndustrial designs in IPR
Industrial designs in IPR
 
Geographical indications
Geographical indicationsGeographical indications
Geographical indications
 
Utility models
Utility modelsUtility models
Utility models
 
Types of oral controll drug delivery system
Types of oral controll drug delivery system Types of oral controll drug delivery system
Types of oral controll drug delivery system
 
Novel drug delivery system
Novel drug delivery systemNovel drug delivery system
Novel drug delivery system
 
Targeted drug delivery system
Targeted drug delivery systemTargeted drug delivery system
Targeted drug delivery system
 

Recently uploaded

Advanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docxAdvanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docx
adhitya5119
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Scholarhat
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Main Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docxMain Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docx
adhitya5119
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
thanhdowork
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRMHow to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
Celine George
 
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments UnitDigital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit
chanes7
 
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingYour Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Excellence Foundation for South Sudan
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Akanksha trivedi rama nursing college kanpur.
 
The basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptxThe basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptx
heathfieldcps1
 
How to Fix the Import Error in the Odoo 17
How to Fix the Import Error in the Odoo 17How to Fix the Import Error in the Odoo 17
How to Fix the Import Error in the Odoo 17
Celine George
 
World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024
ak6969907
 
writing about opinions about Australia the movie
writing about opinions about Australia the moviewriting about opinions about Australia the movie
writing about opinions about Australia the movie
Nicholas Montgomery
 
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold MethodHow to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
Celine George
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
clinical examination of hip joint (1).pdf
clinical examination of hip joint (1).pdfclinical examination of hip joint (1).pdf
clinical examination of hip joint (1).pdf
Priyankaranawat4
 

Recently uploaded (20)

Advanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docxAdvanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docx
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
 
Main Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docxMain Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docx
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRMHow to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
 
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments UnitDigital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit
 
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingYour Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
 
The basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptxThe basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptx
 
How to Fix the Import Error in the Odoo 17
How to Fix the Import Error in the Odoo 17How to Fix the Import Error in the Odoo 17
How to Fix the Import Error in the Odoo 17
 
World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024
 
writing about opinions about Australia the movie
writing about opinions about Australia the moviewriting about opinions about Australia the movie
writing about opinions about Australia the movie
 
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold MethodHow to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
clinical examination of hip joint (1).pdf
clinical examination of hip joint (1).pdfclinical examination of hip joint (1).pdf
clinical examination of hip joint (1).pdf
 

Guidelines on adr reporting

  • 1. Guidelines on ADR reporting Presented by; K. Sai Lakshmi B-Pharmacy, final year, (2016-2020) Balaji College of Pharmacy.
  • 2. A.PATIENT INFORMATION B.SUSPECTED DRUGS C.SUSPECTED ADVERSE DRUG REACTION D.OTHER MEDICATIONS E.REPORTER
  • 3. A. PATIENT INFORMATION; 1.Patient Details  Patient name or initials: A reporter should mention the name of the patient or initials of a patient. For e.g.: Ngawang Dema or ND (whichever is convenient).  Age at time of event or date of birth: A reporter must report either the date of birth or age of the patient at the time the event or reaction occurred.  Sex: A reporter must mention the gender of the patient.  Weight: If known, the weight of the patient should be in kilograms(kg).
  • 4. 2. Relevant tests/Laboratory data  A reporter must mention any laboratory data (if available). 3. Other Relevant history  A reporter must mention any relevant history pertaining to the patient including pre-existing medical conditions e.g.: Allergies, pregnancy, alcohol use, hepatic or renal dysfunction. B. SUSPECTED DRUGS;  It may be one drug or more than one drug.  The details of suspected medications such as the drug name (brand or generic name), manufacturer, batch no / lot no, expiry date, dose used, route used, dates of therapy started and stopped, and indication of use must be provided by the reporter.
  • 5. C. SUSPECTED ADVERSE DRUG REACTION; 1. Describe reaction and any treatment given:  A reporter must briefly describe the event in terms of nature, localization etc. For eg; patient developed rash over upper and lower limbs.  The reporter must be also indicate if any treatment is given againist the Suspected Adverse Drug Reaction.  Reporter must also mention if the suspected drugs was withdrawn or continued.  Date of reaction started; A reporter must the date on which the reaction was first occurred.  Date of reaction stopped; If the reaction recovered, the date on which the reaction recovered should be reported.  Outcomes: The reporter must tick the outcomes of the event as; Recovered- if the patient has recovered from the event Recovering- if the patient is recovering from the existing adverse event Continuing-if the patient is continuing to have the symptoms of the adverse event which occurred.
  • 6. 2. Seriousness of the reaction:  If any event is serious in nature, a reporter must selected the appropriate reason for seriousness e.g.:  Death-if the patient died due to the adverse event  Hospitalization/prolonged-if the adverse event led to hospitalization or increased the hospital stay of the patient.  Life-threatening-if patient was at substantial risk of drying because of the adverse event.  Significant Disability-if the adverse event resulted in a substantial disruption of a person`s ability to conduct normal life functions.  Congenital anomaly-if exposure of drug prior to conception or during pregnancy may have resulted in an adverse outcome in the child.  Other medically significant- when the event does not fit the other outcomes, but the event may put the patient at risk and may require medical or surgical intervention to prevent one of the other outcomes.
  • 7. D. OTHER MEDICATIONS;  A Reporter should include all the details of concomitant drugs including self medication, Over the Counter medication, herbal remedies with therapy dates(start and stop date). E. REPORTER;  Name and Professional address: A reporter must mention his/her name and professional address on the form. The identity of the reporter will be maintained confidential if necessary.  Date of report: Mention the date on which he/she reported the adverse event.
  • 8. NOTE: For quality reporting, all the above mentioned fields are essential. In case of incomplete information, the reporter must take care that at least mandatory fields are present. Following are the mandatory fields for a valid case report and are marked with asterisk on the form:  Patient information: initials, age at onset of reaction, gender.  Suspected adverse reaction: A reaction terms, date of onset of reaction.  Suspected medication: Drug(s) name, dose and date of therapy started, indication of use, seriousness and outcome.  Reporter: Name and address, date of report.